Skip to content
Phoenix Biotechnology, IncPhoenix Biotechnology, Inc
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us
Oleander

Phoenix Biotechnology executes a fourth amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Posted on April 2010June 2022 by Carlos Torres
06
Apr
This entry was posted in Oleander. Bookmark the permalink.
Society of Integrative Oncology (SIO) International Conference- comprehensive poster presentation with discussion.
Publication: Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K+ -ATPase subunits.
Copyright 2023 © Phoenix Biotechnology, Inc. All Rights Reserved. | Terms of Use | Privacy Policy | Cookies Policy
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us